Collaborations & Alliances

Agenus Enters 3 New Clinical Collaborations

Doubles its current number of clinical collaborations by joining forces with Targovax, Oxford BioTherapeutics and Immunogenesis.

Author Image

By: Charlie Sternberg

Associate Editor

Agenus Inc., an immuno-oncology company with a pipeline of therapeutics designed to activate the immune response to cancers and infections, has entered into three new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of clinical collaborations.   These 6 collaborations span a range of Agenus’ clinical assets, including botensilimab (Fc-enhanced anti-CTLA-4), balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4), and QS-21 STIMULON.   ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters